The Year of the Bildil?

Could it be that this year is the turnaround year for Nitromed(NTMD)? With their drug called Bildil which they are getting absolutely hammered on in sales, can they make a push for profitability? Their drug Bildil reduces heart failure by 43% in African Americans. I think with the replacements of the CEO and CFO, they are pumping their blood in the right direction. With NTMD looking to cut costs as a new strategy, I think this new executive staff will get the job done. Let me say this one more time, this is the year of the Bildil. Watch out for new strategic alliances with bigger drugmakers, to cut costs according to the conference call made by NTMD on Wednesday. If all else fails, Someone will pay a premium for this company who has a great product and works well with a soft heart. Currently: $8.22 Price Target: $14

ACT on it!

Act on it now! A stock I recently discovered has a great balance sheet and a cool product is Actions Semiconductor. The company’s products include system-on-a-chips, which are integrated circuits designed to use for both flash memory-based and HDD-based personal media players*. The balance sheet is great and with this cool technology it has room to grow. With over $150 million in revenue and another $130 million in cash and relatively no debt of only $2.3 million this company is where it is at! It also has a P/E under 10! Symbol is ACTS. So you better act before its too late. *Company description and financials provided by Yahoo! Finance. Currently trading at $8.50 Price Target: $ 13.00

Citrus Squeeze?

Another company I want to talk to you about today that I know and love is Jamba Juice. Growing up in California, I went to Jamba Juice every so often, and I gotta tell you, their smoothies rock! They recently agreed to merge with a company called Servies Aquisition who bought them for $265 million. I believe this company knew what they were doing when they bought Jamba Juice, because after all they have a great product and alot of growth potential. According to Yahoo! Finance, Jamba Juice reported sales last year of $345 million at 532 store location worldwide. The thing that I love about this company's future is not only is products of Strawberry Wild or Citrus Squeeze, but that they are likely to start expanding and growing on the east coast. Watch out for a brain freeze from Jamba Juice. Current price: $10.72 Price Target: $15.00

Hot Dog!

Get your hot dogs! A product that I love and most everyone around the world has come to love is the Nathan Hot dog. People love Nathan's because it is a mouth watering and delicious hot dog treat. Personally I love this product and I think it has alot of Growth potential. Trading at only about 15 times earnings and a very good, clean balance sheet, I think this is a no-brainer of a choice. This is the kind of value play you look for in the market. Don't pass this chance up or you might regret not ordering this dog. Current price: $12.18 Target price: $22.00

Having Faith

Good morning to all! I know how important my blog is to all of you out there in blogspace, so I thought I'd type this one up, so you can print it out in between bites of your breakfast.You know I have always liked little biotech plays, so this might not be a surprise to you when I tell you I have found another one. The company is not only trading under $10, but it also is developing several stocks in clinical trials not only one! This comes to a shock to me that it is under $10 a share. It is up alot recently but I think there is still a ton of room to grow. This selection of diversafication of drugs in their pipeline is huge! This is why I'm going to add AVI Biopharma Inc. (AVII) to my stocks to watch. Hope to see you at $20 currently at: $7.25